Page 417«..1020..416417418419

Biotech-center director sees big step ahead – Winston-Salem Journal

By Dr. Matthew Watson


Triad Business Journal
Biotech-center director sees big step ahead
Winston-Salem Journal
Nancy Johnston says she believes that the Triad's biotechnology sector is on the cusp of taking a major step forward in ...
Johnston to lead biotech centerWinston-Salem Journal
Biotech Center picks marketing executive to lead Piedmont Triad officeLocal Tech Wire (blog)

all 5 news articles »

To Read More: Biotech-center director sees big step ahead – Winston-Salem Journal
categoriaUncategorized commentoComments Off on Biotech-center director sees big step ahead – Winston-Salem Journal | dataMay 5th, 2010
Read All

2010 BIO International Convention opens in Chicago – Xinhua

By Dr. Matthew Watson


Xinhua
2010 BIO International Convention opens in Chicago
Xinhua
CHICAGO, May 4 (Xinhua) -- 2010 BIO (Biotechnology Industry Organization) International Convention, the world's largest gathering of the global biotech ...
BioCurex, Inc. Executive Chairman Denis Burger to Present at the Renowned BIO ...MarketWatch (press release)
Patrick cancels BIO visit amid water crisisBizjournals.com
Biotech industry provides almost 25000 jobs in state, report saysMadison.com
Kaiser Health News -Mass High Tech -india-server.com
all 129 news articles »

To Read More: 2010 BIO International Convention opens in Chicago – Xinhua
categoriaUncategorized commentoComments Off on 2010 BIO International Convention opens in Chicago – Xinhua | dataMay 5th, 2010
Read All

Patent Applications Backed Up: So Are New Jobs – Inventorspot

By Dr. Matthew Watson


Patently-O
Patent Applications Backed Up: So Are New Jobs
Inventorspot
Patents created jobs during the Industrial Revolution and patents need to continue to create jobs in the digital and biotechnology age. ...
Backlog of patents still stifling potential jobs, director saysMilwaukee Journal Sentinel
Stem Cell Patents Under FireGoozNew (blog)
Kappos Talks Patent Reform and Gene Patents at BIO ConventionIPWatchdog.com

all 170 news articles »

To Read More: Patent Applications Backed Up: So Are New Jobs – Inventorspot
categoriaUncategorized commentoComments Off on Patent Applications Backed Up: So Are New Jobs – Inventorspot | dataMay 5th, 2010
Read All

Governor Martin O’Malley Named BIO Governor of the Year – Citybizlist (press release)

By Dr. Matthew Watson


Crain's Chicago Business
Governor Martin O'Malley Named BIO Governor of the Year
Citybizlist (press release)
BALTIMORE, MD (May 3, 2010) - Recognized for his outstanding leadership in growing and promoting Maryland's biotechnology industry, Governor Martin O'Malley ...
Author : Biotechnology Industry OrganizationEarthtimes (press release)
Latest biotech industry report shows Wisconsin gaining jobsWTN News
Wisconsin biotech industry growsThe Business Journal
Minneapolis Star Tribune -PR Newswire (press release) -ThomasNet Industrial News Room (press release)
all 71 news articles »

To Read More: Governor Martin O’Malley Named BIO Governor of the Year – Citybizlist (press release)
categoriaUncategorized commentoComments Off on Governor Martin O’Malley Named BIO Governor of the Year – Citybizlist (press release) | dataMay 4th, 2010
Read All

researchers awarded $4 million in grants from state stem cell agency – UC Los Angeles

By Dr. Matthew Watson


Times Online
researchers awarded $4 million in grants from state stem cell agency
UC Los Angeles
... an associate professor of microbiology, immunology and molecular genetics, who was awarded $1.37 million and whose grant received the highest score; ...
UCI Basic Research On Stem Cells Funded By CaliforniaMedical News Today (press release)

all 74 news articles »

To Read More: researchers awarded $4 million in grants from state stem cell agency – UC Los Angeles
categoriaUncategorized commentoComments Off on researchers awarded $4 million in grants from state stem cell agency – UC Los Angeles | dataMay 3rd, 2010
Read All

Health care reform bill dooms America to Pharma-dominated sickness and suffering

By Dr. Matthew Watson

Today the medical mafia struck another devastating blow to the health and freedom of all Americans. With the support of an inarguably corrupt Congress that has simply abandoned the real needs of the American people, the sick-care industry has locked in a high-profit scheme of disease and monopoly-priced pharmaceuticals in a nation that can ill afford either one.

And this Pharma-funded betrayal, it turns out, was led by the Democrats. Passed on a 219-212 vote that was only accomplished thanks to closed-door, last-minute secret meetings among the last holdouts, this new legislation puts America under the stranglehold of the medical mafia while doing absolutely nothing to address real health care reform. There is no mention in the bill Read more...

Youtharia for Anti-Aging & Longevity

To Read More: Health care reform bill dooms America to Pharma-dominated sickness and suffering
categoriaIntegrative Medicine commentoComments Off on Health care reform bill dooms America to Pharma-dominated sickness and suffering | dataMay 3rd, 2010
Read All

Court hears arguments today on genetic engineering of crops – SuburbanJournals

By Dr. Matthew Watson


AFP
Court hears arguments today on genetic engineering of crops
SuburbanJournals
WASHINGTON -- The US Supreme Court today will hear oral arguments in a case involving Monsanto Co., the high court's first case dealing with genetically ...
Court hears arguments today on genetic engineering of cropsTrading Markets (press release)
Supreme Court hearing on GMO AlfalfaBiofortified (blog)
Both Sides Optimistic After US Supreme Court HearingMichigan Farmer

all 263 news articles »

To Read More: Court hears arguments today on genetic engineering of crops – SuburbanJournals
categoriaUncategorized commentoComments Off on Court hears arguments today on genetic engineering of crops – SuburbanJournals | dataMay 2nd, 2010
Read All

Dendreon leads drug stocks higher – MarketWatch

By Dr. Matthew Watson


Artuji
Dendreon leads drug stocks higher
MarketWatch
The NYSE Arca Pharmaceutical Index (INDEX:DRG) edged up 0.4% at 299.09 and the NYSE Arca Biotechnology Index (INDEX:BTK) rose 0.7% to 1227.88.
Dendreon's Clean Bill Of HealthForbes
Major turnaround for Dendreon as US FDA approves Provenge for advanced ...The Pharma Letter
Dendreon Shares Pop On Provenge ApprovalDaily Markets
Orange County Business Journal -Puget Sound Business Journal -Comtex Smartrend
all 976 news articles »

To Read More: Dendreon leads drug stocks higher – MarketWatch
categoriaUncategorized commentoComments Off on Dendreon leads drug stocks higher – MarketWatch | dataMay 2nd, 2010
Read All

CSC news links 2010-05-01

By Dr. Matthew Watson

For links to recent news items, visit these [Twitter] or [FriendFeed] pages. Examples of two news items that have received attention:?

To Read More: CSC news links 2010-05-01
categoriaStem Cell Therapy commentoComments Off on CSC news links 2010-05-01 | dataMay 2nd, 2010
Read All

More about presentations at AACR10

By Dr. Matthew Watson

Five presentations at the 101th annual meeting of the American Association of Cancer Research were highlighted a news release from Geron Corporation (dated March 3, 2010). One presentation that had an explicit focus on CSC was this poster:

Imetelstat, a telomerase inhibitor in phase I trials in solid tumor and hematological malignancies, has broad activity against multiple types of cancer stem cells [Presentation Abstract].

Also mentioned in the news release was an oral presentation by Jerry W Shay, given as part of the Major Symposium entitled: Role of Telomeres and Telomerase in Chromosomal Stability and Disease [Session Detail]. The presentation was:

Role of telomerase in normal and neoplastic stem cells [Presentation Abstract].

Another poster about the telomerase inhibitor imetelstat (GRN163L) was:

Sensitivity and resistance of non-small cell lung cancer to the telomerase inhibitor imetelstat [Presentation Abstract].

Comments: A search of the ClinicalTrials.gov database for GRN163L revealed 6 trials. Four were ongoing, but not recruiting participants. Two were still recruiting: 1) Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies; 2) A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer.

An analogous search for imetelstat yielded the same 6 trials. All 6 trials have been sponsored by Geron Corporation.

To Read More: More about presentations at AACR10
categoriaStem Cell Therapy commentoComments Off on More about presentations at AACR10 | dataMay 2nd, 2010
Read All

Dendreon’s Clean Bill Of Health – Forbes

By Dr. Matthew Watson


Santa Barbara Independent
Dendreon's Clean Bill Of Health
Forbes
One of the most controversial biotechnology companies of the past decade is poised to become one of the most successful. The Food and Drug Administration ...
FDA approves country's first cancer treatment vaccineSeattle Times
FDA Approves Drug for Company with Seal Beach PlantOrange County Business Journal
Business Journal Live on the Eastside with Dendreon Chief Dr. Mitchell GoldPuget Sound Business Journal
Comtex Smartrend -Reuters -Santa Barbara Independent
all 695 news articles »

To Read More: Dendreon’s Clean Bill Of Health – Forbes
categoriaUncategorized commentoComments Off on Dendreon’s Clean Bill Of Health – Forbes | dataApril 30th, 2010
Read All

Latest Cell Therapy Approval by FDA. Dendreon’s Provenge.

By Dr. Matthew Watson

It has been a long-time coming. It has been hyped and scoffed, bet against and hoped for, but now none of that matters. It's here. Dendreon has brought Provenge to market. Here, in the word's of the FDA...

FDA NEWS RELEASE

For Immediate Release: April 29, 2010

FDA Approves a Cellular Immunotherapy for Men with Advanced Prostate Cancer

The U.S. Food and Drug Administration today approved Provenge (sipuleucel-T), a new therapy for certain men with advanced prostate cancer that uses their own immune system to fight the disease.

Provenge is indicated for the treatment of asymptomatic or minimally symptomatic prostate cancer that has spread to other parts of the body and is resistant to standard hormone treatment.

Prostate cancer is the second most common type of cancer among men in the United States, behind skin cancer, and usually occurs in older men. In 2009, an estimated 192,000 new cases of prostate cancer were diagnosed and about 27,000 men died from the disease, according to the National Cancer Institute.

“The availability of Provenge provides a new treatment option for men with advanced prostate cancer, who currently have limited effective therapies available,” said Karen Midthun, M.D., acting director of the FDA’s Center for Biologics Evaluation and Research.

Provenge is an autologous cellular immunotherapy, designed to stimulate a patient’s own immune system to respond against the cancer. Each dose of Provenge is manufactured by obtaining a patient’s immune cells from the blood, using a machine in a process known as leukapheresis. To enhance their response against the cancer, the immune cells are then exposed to a protein that is found in most prostate cancers, linked to an immune stimulating substance. After this process, the patient’s own cells are returned to the patient to treat the prostate cancer. Provenge is administered intravenously in a three-dose schedule given at about two-week intervals.

The effectiveness of Provenge was studied in 512 patients with metastatic hormone treatment refractory prostate cancer in a randomized, double-blind, placebo-controlled, multicenter trial, which showed an increase in overall survival of 4.1 months. The median survival for patients receiving Provenge treatments was 25.8 months, as compared to 21.7 months for those who did not receive the treatment.

Almost all of the patients who received Provenge had some type of adverse reaction. Common adverse reactions reported included chills, fatigue, fever, back pain, nausea, joint ache and headache. The majority of adverse reactions were mild or moderate in severity. Serious adverse reactions, reported in approximately one quarter of the patients receiving Provenge, included some acute infusion reactions and stroke. Cerebrovascular events, including hemorrhagic and ischemic strokes, were observed in 3.5 percent of patients in the Provenge group compared with 2.6 percent of patients in the control group.

Provenge is manufactured by Seattle-based Dendreon Corp.

To Read More: Latest Cell Therapy Approval by FDA. Dendreon’s Provenge.
categoriaRegenerative Medicine commentoComments Off on Latest Cell Therapy Approval by FDA. Dendreon’s Provenge. | dataApril 30th, 2010
Read All

Malaysia To Showcase Bio-Xcell, Biotech Advantages At BIO Chicago – Bernama

By Dr. Matthew Watson


Earthtimes (press release)
Malaysia To Showcase Bio-Xcell, Biotech Advantages At BIO Chicago
Bernama
The 70-member delegation, with extensive biotechnology background, will "rub shoulders" with Who's Who in the biotechnology industry to convince them on the ...
Tennessee Biotechnology Association Announces Speaker Lineup for BIO ...Earthtimes (press release)
Baxter Welcomes BIO 2010 International Convention to ChicagoMarketWatch (press release)
2010 BIO International Convention Exhibitor ProfilesBusiness Wire (press release)
PR Newswire (press release) -Bradenton Herald
all 132 news articles »

To Read More: Malaysia To Showcase Bio-Xcell, Biotech Advantages At BIO Chicago – Bernama
categoriaUncategorized commentoComments Off on Malaysia To Showcase Bio-Xcell, Biotech Advantages At BIO Chicago – Bernama | dataApril 30th, 2010
Read All

BioCryst rallies on gout study; indices diverge – MarketWatch

By Dr. Matthew Watson


HealthNewsDigest.com
BioCryst rallies on gout study; indices diverge
MarketWatch
The NYSE Arca Pharmaceutical Index (INDEX:DRG) was down marginally at 293.68 while the NYSE Arca Biotechnology Index (INDEX:BTK) rose 0.6% to 1178.34.
BioCryst Reports Positive Results from Part One of Its Phase 2a Study of ...MarketWatch (press release)
BioCryst says gout drug shows positive resultsReuters

all 40 news articles »

To Read More: BioCryst rallies on gout study; indices diverge – MarketWatch
categoriaUncategorized commentoComments Off on BioCryst rallies on gout study; indices diverge – MarketWatch | dataApril 29th, 2010
Read All

Biotech Firms Seek Speedier Reviews of Seeds – Truth about Trade & Technology

By Dr. Matthew Watson


France24
Biotech Firms Seek Speedier Reviews of Seeds
Truth about Trade & Technology
The crop-biotechnology industry, growing frustrated as it watches the approval time for new seeds almost double under the Obama ...
Hear Ye, Hear Ye. Judging BiotechnologyCattleNetwork.com
Both Sides Optimistic After US Supreme Court HearingMichigan Farmer
Supreme Court Hears Case on GM Alfalfa BanThe Epoch Times
Iowa Independent -PR Newswire (press release)
all 238 news articles »

To Read More: Biotech Firms Seek Speedier Reviews of Seeds – Truth about Trade & Technology
categoriaUncategorized commentoComments Off on Biotech Firms Seek Speedier Reviews of Seeds – Truth about Trade & Technology | dataApril 29th, 2010
Read All

Charles River Buys Chinese Drug Research Firm – New York Times

By Dr. Matthew Watson


Boston Globe
Charles River Buys Chinese Drug Research Firm
New York Times
The merger reflects the shifting dynamics of the global pharmaceutical and biotechnology industries. Because a major new drug now takes 10 to 15 years and ...
Charles River to buy WuXi for $1.6bBoston Globe
Merger: American firm buys Chinese pharma companyBusiness Review USA
Charles River buys WuXi PharmaTech in $1.6 billion dealFinanceAsia
theasset.com -Mass High Tech -MarketWatch (press release)
all 352 news articles »

To Read More: Charles River Buys Chinese Drug Research Firm – New York Times
categoriaUncategorized commentoComments Off on Charles River Buys Chinese Drug Research Firm – New York Times | dataApril 28th, 2010
Read All

Stem cells for a Webby!

By Dr. Matthew Watson

I know I haven't been a very good blogger for quite some time but I wanted to pass on a letter I just received from my friend James Price as a Charter member of the Canadian Stem Cell Foundation. They're going for a Webby award. You don't have to be Canadian to support their cause - you just have to:

  • believe in the power of interactive, online network-based activism,
  • support the potential of stem cells to change people's lives, and
  • wanna have a little fun raising awareness for our otherwise-sometimes-stodgy-science!

Go vote - it's good for you and the world! (WARNING: you might find out some things about some pretty cool stuff nominated in the other categories while you're there).

CSCFHeader

Dear Lee,

I'd like to thank everyone who has voted and helped spread the word about the Webby Awards nomination. We think a big part of the Foundation's success, and especially this nomination, is due to your enthusiasm, creativity and support.

That support has taken us a long way. Right now, we're in the lead for Best Activism Website. But our lead is narrow, only 3%, so we need you to pull out all the stops. There are only two days left to vote, so let's make sure it's a win for stem cells!

Why Activism?

A large part of what makes our website and social media pages work is the Charter community. All the material we create - the Stem Cell Charter, "Rock Star Scientists" video and all the posts on our social media pages - are designed to give the stem cell movement a voice - your voice. You are the most important part of getting the word out about stem cell science and helping people see the amazing potential of the field.

Voting and encouraging others to vote is a perfect way to do this. Tweet, post, blog, email and shout your support from the rooftops. Let's show the world how important we think stem cell science is.

How to vote

Step 1: Click HERE and fill in your email address and a password.

Step 2: You will receive an email from the Webby Awards - click the link to activate your account.

Step 3: Go HERE TO VOTE and choose RENEW THE WORLD.

Voting closes at midnight on April 29th. We have two days left!

webby banner

Thanks for your support,


James Price
President & CEO



To Read More: Stem cells for a Webby!
categoriaRegenerative Medicine commentoComments Off on Stem cells for a Webby! | dataApril 28th, 2010
Read All

Court hears arguments today on genetic engineering of crops – Trading Markets (press release)

By Dr. Matthew Watson


AFP
Court hears arguments today on genetic engineering of crops
Trading Markets (press release)
Monsanto Co. argued in front of the US Supreme Court this morning that a lower court erred by imposing an injunction that prevents the planting of ...
Court hears arguments today on genetic engineering of cropsSuburbanJournals
Supreme Court hearing on GMO AlfalfaBiofortified (blog)

all 197 news articles »

To Read More: Court hears arguments today on genetic engineering of crops – Trading Markets (press release)
categoriaUncategorized commentoComments Off on Court hears arguments today on genetic engineering of crops – Trading Markets (press release) | dataApril 28th, 2010
Read All

Beetroot Juice May Boost Stamina

By Dr. Matthew Watson

(HealthDay News) -- Beetroot juice can boost physical stamina and increase exercise endurance by up to 16 percent, a new British study shows.

The researchers found that nitrate in beetroot juice reduces oxygen uptake to a degree that can't be achieved by any other means. The findings could benefit endurance athletes, elderly people and those with cardiovascular, respiratory or metabolic diseases, the study authors suggest.

The study included eight men, aged 19 to 38, who drank 500 milliliters a day of organic beetroot juice for six consecutive days. They then completed a series of tests on an exercise bike. The same tests were repeated after the men drank the same amount of a placebo (blackcurrant cordial) for six days.

After drinking the beetroot juice, the men were able to cycle for an average of 11.25 minutes -- 92 seconds longer than after consuming the placebo drink. The men also had a lower resting blood pressure after they drank the beetroot juice, the researchers found.

The study was published Aug. 6 in the Journal of Applied Physiology. Read more...



Joint Mender for Joint Care

To Read More: Beetroot Juice May Boost Stamina
categoriaIntegrative Medicine commentoComments Off on Beetroot Juice May Boost Stamina | dataApril 27th, 2010
Read All

Biomarker Studies Could Realize Goal of More Effective and Personalized Cancer Medicine

By Dr. Matthew Watson

When President Richard Nixon launched the war on cancer in his January 1971 State of the Union, he called for "the same kind of concentrated effort that split the atom and took man to the moon." Yet nearly 40 years and $100 billion in federally funded cancer research later, it seems the lunar landing was a much less daunting task.

[More]

Add to digg
Add to StumbleUpon
Add to Reddit
Add to Facebook
Add to del.icio.us
Email this Article


To Read More: Biomarker Studies Could Realize Goal of More Effective and Personalized Cancer Medicine
categoriaUncategorized commentoComments Off on Biomarker Studies Could Realize Goal of More Effective and Personalized Cancer Medicine | dataApril 27th, 2010
Read All

Page 417«..1020..416417418419